2024 National Immunoglobulin (Ig) Treatment Survey

Who took the survey?

854 individuals completed the survey between May and August 2024. Note that because not every respondent answered every question, the number of respondents who answered each question is given for each analysis (n=).

• The most reported diagnoses were common variable immune deficiency (CVID; 71%), hypogammaglobulinemia (12%), and specific antibody deficiency (6%).
• 92% of respondents identified as white, 3% identified as two or more races or ethnicities, 2% identified as Hispanic/Latino, 1% identified as Black/American African, 1% identified as American Indian/Alaska Native, and 1% identified as Asian/Pacific Islander.
• Respondents ranged in age from 2-89 years old, with a median age of 59 years old.
• 14.6% of patients were male at birth, while 85.2% were female and 0.1% were intersex at birth.

Explore survey results

Explore select 2024 National Ig Treatment Survey results using this interactive dashboard (note that the dashboard works best on laptop or desktop computers). How to use the dashboard:

• Use the slider at the bottom right to zoom in or the double-headed diagonal arrow to view full screen.
• Navigate through four pages of data (General health, IgRT and side effects, Serious adverse events, and Treatment satisfaction) using the arrows in the bottom grey bar.
• Interested in a particular group of respondents? Filter the data on each page using the navy blue dropdown menus at the top.